David A. Horne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
David A. Horne has a total of 165 co-authors. Here are the top co-authors by number of shared publications:
- Baojun Wang
Senior Department of Urology, Chinese PLA General Hospital, Beijing, China
18 shared publications - Chunyu Zhang
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
18 shared publications - Gong-Hong Wei
Fudan University Shanghai Cancer Center & MOE Key Laboratory of Metabolism and Molecular Medicine and Department of Biochemistry and Molecular Biology of School Basic Medical Sciences, Shanghai Medi
18 shared publications - Hao Peng
Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
18 shared publications - Jianbo Tian
Department of Epidemiology and Biostatistics, School of Public Health; State Key Laboratory of Metabolism and Regulation in Complex Organisms, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, China
18 shared publications - Jing Li
Department of Precision Medicine, Changhai Hospital, Second Military Medical University
18 shared publications
Latest Publications
- Open Access
- 13 March 2026
- Published by Springer Nature in Research Square
H3K9me3 inhibition reverses Alzheimer′s progression by restoring synaptic and immune proteostasis across the brain–retina axis
Epigenetic dysregulation is increasingly linked to ageing and neurodegeneration, yet its contribution to retinal and brain pathology in Alzheimer's disease (AD) remains uncharacterized. We quantified the repressive histone mark H3K9me3 in post-mortem retinas and brains from donors spanning normal cognition, mild cognitive impairment, and AD dementia. In both tissues, H3K9me3 increased in early stages and further in AD dementia, strongly associating with cognitive status and neuropathological burden. To assess causality, we inhibited the H3K9 methyltransferase SUV39H1 in APPswe/PS1dE9 and APPswe/tauP301L/PS1tm1Mpm mouse models. SUV39H1 inhibition lowered H3K9me3, mitigated AD-like pathology, restored synaptic integrity, and improved cognitive and visual performance. Proteomics revealed that H3K9me3 derepression reestablished retinal and brain proteostasis and promoted neuroprotection through immunomodulatory pathways and BDNF/VGF–granin signalling. These findings identify H3K9me3 as shared epigenetic driver of AD-related dysfunction, highlight H3K9me3 reduction as therapeutic strategy, and position the retina as an accessible extension of the brain for epigenetic studies.
- 13 March 2026
- Published by Springer Nature in Research Square
Open AccessH3K9me3 inhibition reverses Alzheimer′s progression by restoring synaptic and immune proteostasis across the brain–retina axis
Epigenetic dysregulation is increasingly linked to ageing and neurodegeneration, yet its contribution to retinal and brain pathology in Alzheimer's disease (AD) remains uncharacterized. We quantified the repressive histone mark H3K9me3 in post-mortem retinas and brains from donors spanning normal cognition, mild cognitive impairment, and AD dementia. In both tissues, H3K9me3 increased in early stages and further in AD dementia, strongly associating with cognitive status and neuropathological burden. To assess causality, we inhibited the H3K9 methyltransferase SUV39H1 in APPswe/PS1dE9 and APPswe/tauP301L/PS1tm1Mpm mouse models. SUV39H1 inhibition lowered H3K9me3, mitigated AD-like pathology, restored synaptic integrity, and improved cognitive and visual performance. Proteomics revealed that H3K9me3 derepression reestablished retinal and brain proteostasis and promoted neuroprotection through immunomodulatory pathways and BDNF/VGF–granin signalling. These findings identify H3K9me3 as shared epigenetic driver of AD-related dysfunction, highlight H3K9me3 reduction as therapeutic strategy, and position the retina as an accessible extension of the brain for epigenetic studies.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
NCOA4 promotes ferroptosis in prostate cancer.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
NCOA4 promotes ferroptosis in prostate cancer.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
NCOA4 is related to the progression of prostate cancer.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
NCOA4 is related to the progression of prostate cancer.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
Time-dependent ROC curves and calibration plots assessing the prognostic performance of the ferroptosis-related gene signature.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
Time-dependent ROC curves and calibration plots assessing the prognostic performance of the ferroptosis-related gene signature.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
Construction and validation of ferroptosis-related gene signature
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
Construction and validation of ferroptosis-related gene signature
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
Summary of characteristics of individuals
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
Summary of characteristics of individuals
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
The function associated with variants in DARs in prostate cancer
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
The function associated with variants in DARs in prostate cancer
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
Summary of prognostic performance metrics for the ferroptosis gene signature across three prostate cancer cohorts.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
Summary of prognostic performance metrics for the ferroptosis gene signature across three prostate cancer cohorts.
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
NCOA4 affects prostate cancer sensitivity to ferroptosis-inducing drug in vitro
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
NCOA4 affects prostate cancer sensitivity to ferroptosis-inducing drug in vitro
- Open Access
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
ZNF384 regulates NCOA4 through binding to the mutant allele of rs7077830.
- 1 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Integrated Omics and Multicohort Analyses Identify an Enhancer Variant Linking Ferroptosis to Precision Therapy in Prostate Cancer
ZNF384 regulates NCOA4 through binding to the mutant allele of rs7077830.